Optiscan Imaging

Optiscan Imaging is a global leader in confocal endomicroscopy, with a mission to enable informed decisions for optimized healthcare through real-time, single-cell imaging. Founded in 1993, the company has developed a proprietary, miniaturized platform that integrates into endoscopes and handheld devices, providing instant digital pathology during procedures. Its strategy focuses on commercializing systems for clinical applications like surgical margin detection while expanding into new markets such as robotic surgery and AI-driven diagnostics. Optiscan is a publicly traded company (ASX: OIL) driving a paradigm shift from traditional biopsy to immediate optical biopsy.

Proprietary, miniaturized confocal laser endomicroscopy platform that creates a pen-sized digital microscope probe for real-time, non-destructive, in-vivo imaging at the single-cell level.

Optiscan's primary direct competitor is Mauna Kea Technologies (Cellvizio). It also faces competition from the entrenched standard of frozen section analysis and alternative intraoperative imaging technologies like OCT. Its competitive edge lies in its proprietary miniaturization, single-cell resolution, and multi-application platform strategy.